The Ohio State University Medical Center Acquires Mobetron from Intraop Medical, Inc.

[October 2004]  Intraop Medical, Inc. announced this month that it had received an order for a Mobetron from the Arthur James Cancer Hospital at The Ohio State University Medical Center. The Mobetron will replace an intraoperative radiation therapy (“IORT”) treatment system that has been in clinical use since the early 1990’s. The Arthur James Cancer Hospital at the Ohio State University Medical Center has one of the world’s premier IORT programs. They have conducted and published numerous clinical studies that integrate IORT in the treatment of cancer patients, including studies for patients with head and neck cancer, rectal cancer, gynecological cancer and pediatric cancers.

“Having a Mobetron installed at one of the world’s recognized leading IORT centers is extremely gratifying”, says Donald A. Goer, President & CEO of Intraop Medical, Inc. “This affords us the opportunity of expanding our customer base while continuing to work with premier research centers to develop new IORT protocols and applications.” We are already working with the Arthur James Cancer Hospital and other centers on an IORT lung protocol (See accompanying news story). We look forward to strengthening our collaborations with IORT research centers throughout the world.”

“The Mobetron will enable us to continue to provide electron beam IORT treatments for our patients,” says Dr. Subir Nag, Director of Intraoperative Radiation Therapy and Brachytherapy at the Arthur James Cancer Hospital. “IORT is an important tool in our cancer treatment armamentarium. Because we can usually displace or protect normal tissues during the treatment, IORT allows us to increase the delivered dose to the patient substantially. For some patients with advanced disease this dose escalation may make the difference in controlling the tumor growth. We look forward to working with Intraop to continue to develop and expand IORT applications.”

The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University is one of only 38 National Cancer Institute-designated Comprehensive Cancer Centers in the United States and the only freestanding cancer hospital in the Midwest. Here specialists in every form of oncology are wholly committed to providing the highest level of cancer prevention, detection, treatment, education, and research, using different modalities to provide patients a multidisciplinary approach for cancer treatment. The cancer hospital has been performing IORT since the early 1990’s.